Anarexol

Quick links to important sections

Anarexol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anarexol

Property Description
Active Ingredient Cyproheptadine hydrochloride
Form Tablet, Syrup, Oral Solution
Pharmacological Class First-Generation Antihistamine
General Purpose Relief of allergic symptoms and pruritus
Origin Synthetic

Anarexol: Definition and Pharmacological Classification

Anarexol is a pharmaceutical preparation whose active component is Cyproheptadine hydrochloride, fundamentally classified as a potent, synthetic first-generation antihistamine. This classification means it belongs to an established class of drugs used primarily to counter the body's allergic response. Its chemical identity derives from the piperidine group, and it is typically designated as a prescription-only drug. As a single-ingredient product, its effects are defined exclusively by Cyproheptadine, which is recognized as an H1 receptor antagonist.


Dual Action and General Therapeutic Purpose

The medicine is clinically recognized for its dual physiological action: it functions as a competitive H1-receptor antagonist and, notably, as an antiserotonergic agent. This dual mechanism is intended to alleviate the overall burden of symptoms associated with various allergic conditions, especially those involving severe skin reactions and persistent pruritus (itching). The H1 antagonism is a standard function, but its secondary antiserotonergic property is a key differentiating factor, making it relevant when traditional antihistamines might be insufficient. The inherent sedative effect of this first-generation agent is a critical property to consider.


Available Forms and Administration

Anarexol is formulated for oral administration and is available in multiple dosage forms for patient convenience, including a solid tablet, as well as liquid preparations such as an oral solution or syrup. The availability of the syrup and oral solution forms ensures greater ease of administration for specific patient groups, such as children or the elderly, who may have difficulty swallowing tablets. Regardless of the form, the core composition remains the single active substance, Cyproheptadine hydrochloride, combined with either an excipient matrix or an aqueous liquid base, guaranteeing consistent delivery of the therapeutic agent regardless of the chosen form.

Regulatory References

  1. NIH MedlinePlus Cyproheptadine Information
  2. NIH LiverTox Cyproheptadine Monograph

What side effects are possible with Anarexol?

Possible Side Effects and Safety Information

The safety profile for Anarexol (Cyproheptadine) is officially documented by regulatory authorities, with adverse reactions generally classified across several physiological systems.

Key Regulatory Classifications

The most common and frequently reported adverse effects relate to the Central Nervous System (CNS) and are often described as transient, meaning they may be most prominent at the initiation of treatment. These effects include sedation, sleepiness (drowsiness), and dizziness.

Adverse reactions are further categorized by System-Organ Class (SOC) in official labeling:

  • CNS Disorders: Includes confusion, excitation, nervousness, tremor, and, rarely, convulsions.
  • Gastrointestinal Disorders: Effects such as dryness of mouth, epigastric distress, nausea, and constipation are documented.
  • Hepatobiliary and Blood Disorders: The official profile notes the potential for rare, serious adverse reactions including hepatic failure, jaundice, and severe blood dyscrasias like agranulocytosis and hemolytic anemia.

Population-Specific Safety Statements

Official documents outline specific safety considerations for certain groups. Elderly patients are more susceptible to adverse effects such as sedation, dizziness, and hypotension. The labeling also notes that pediatric patients may, on rare occasions, experience paradoxical excitation. Furthermore, the use of this medicine is contraindicated in nursing women due to the risk of serious adverse reactions to the infant, as stated in regulatory materials.

Official safety statements restrict use in patients with certain conditions, such as narrow-angle glaucoma or pyloroduodenal obstruction, or when used concomitantly with Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory documents outline that an overdose of Anarexol (Cyproheptadine hydrochloride) requires immediate medical attention due to the potential for severe and life-threatening complications. Help must be sought immediately for any suspected exposure to excessive amounts of the medicine.

Overdose may present with varied manifestations, including pronounced effects on the central nervous system (CNS):

Classification Documented Overdose Manifestations
CNS Effects Drowsiness, sedation, or progression to coma. Paradoxical stimulation: agitation, hallucinations, convulsions, or tremor.
Systemic Effects Tachycardia (rapid heart rate), flushing, dry mouth, dilated pupils, and urinary retention.

Life-threatening outcomes documented in official labeling include respiratory arrest, cardiac arrest, and death. Pediatric patients (infants and young children) are noted to be especially vulnerable to the severe outcomes of CNS excitation, convulsions, and cardiopulmonary arrest.

Management is primarily symptomatic and supportive. Regulatory guidance describes immediate procedures such as decontamination via gastric lavage or the use of activated charcoal. Hospital monitoring, including vital sign monitoring and ECG, may be required to manage severe cardiovascular and neurological complications.

Therapeutic Uses of Anarexol

Anarexol (Cyproheptadine) is applied across domains where additional symptomatic support is needed and helps ease the overall symptom burden of distressing manifestations. This multifaceted use includes application for various allergic conditions and certain headaches.

The medication is relevant in contexts involving heightened systemic burden and is used across conditions presenting with acute episodes, including chronic urticaria (hives), allergic dermatoses leading to intense pruritus (itching), seasonal and perennial allergic rhinitis, and the prophylactic management of vascular headaches, such as migraines. Beyond allergic conditions, it is applied across domains where additional symptomatic support is needed, relevant in clinical settings that involve poor nutritional intake.

Applied during phases of increased distress or discomfort, it provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations. The medication plays a role in managing symptoms that interfere with daily comfort and cause noticeable physiological strain.


Quick Fact: Symptom Management in Persistent Pruritus and Allergic Rhinitis Anarexol is commonly used when symptoms related to systemic imbalance (like severe allergic itching) or heightened physiological activity (like constant sneezing) require additional management of discomfort. Its supportive relief contributes to maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Anarexol

This section outlines the population eligibility and non-eligibility for Anarexol (Cyproheptadine hydrochloride) as defined strictly by official government regulatory documentation.


Populations for Whom Use is Prohibited

Use of Anarexol is contraindicated in several specific populations and clinical states, meaning the medicine must not be used:

  • Infants: Newborn or premature infants and children under two years of age (safety/effectiveness not established).
  • Lactation: Nursing mothers are prohibited from using the medicine.
  • Specific Comorbidities: Patients with angle-closure glaucoma, symptomatic prostatic hypertrophy, stenosing peptic ulcer, or pyloroduodenal obstruction.
  • Concurrent Therapy: Patients currently receiving MAO inhibitor therapy.

Approved and Restricted-Use Populations

Anarexol is approved for use in adults and older pediatric patients (2 years of age and older). Use is restricted or requires caution in several groups:

  • Geriatric Patients: Debilitated elderly patients are contraindicated, while others require cautious dose selection.
  • Physiological Status: Use in pregnancy is advised only if clearly needed (Category B).
  • Organ Function/Comorbidity: Patients with renal insufficiency, history of bronchial asthma, hyperthyroidism, or cardiovascular disease should use the medicine with caution.

What should I know about interactions with other medicines?

The interaction profile for Anarexol is defined primarily by its pharmacodynamic properties, which necessitate specific constraints on co-administration with other substances.

Interaction Scope

Property Official Regulatory Information
Medicinal Product Categories Monoamine Oxidase Inhibitors (MAOIs) and Central Nervous System (CNS) Depressants (including hypnotics, sedatives, tranquilizers, and antianxiety agents).
Mechanistic Basis Pharmacodynamic interaction leading to additive effects of CNS depression and the intensification of anticholinergic effects.
Population Notes Elderly, debilitated patients are noted as being at increased risk for interaction-related outcomes, such as heightened dizziness, sedation, and hypotension.
Timing Rules No specific timing separation requirements are officially stated for co-administration.

Interaction Classifications

Property Official Regulatory Information
Interaction Severity Contraindicated (for MAOIs) and Clinically Significant Risk (for CNS depressants and alcohol).
Interaction-Context Constraint The consumption of alcohol is documented to have additive effects with Anarexol, contributing to increased CNS depression.

Official Interaction Statements

  • Co-administration with Monoamine Oxidase Inhibitor (MAOI) therapy is formally contraindicated. MAOIs are noted to prolong and intensify the anticholinergic effects of the medicine.
  • Additive Central Nervous System (CNS) depression effects occur when co-administered with alcohol and other CNS depressants.

The official regulatory documents define the product’s interaction structure around these pharmacodynamic risks and prohibited uses. The core interaction risk involves the potentiation of sedative and anticholinergic effects, which is further amplified in specific populations as noted in the label.

Mechanism of Action

Anarexol (Cyproheptadine) acts by engaging multiple receptor-mediated signaling pathways, exhibiting antiserotonergic and anticholinergic properties, in addition to its primary action as a first-generation antihistamine.


Histamine H1 Receptor Antagonism

This mechanistic domain involves Anarexol's competitive binding to histamine H1 receptors on effector cells. By blocking these receptors, the drug suppresses the signaling cascade initiated by endogenous histamine, altering the activity state of downstream physiological pathways.


Serotonin Receptor Modulation

Anarexol acts as an antagonist at various serotonin receptors, particularly the 5 -HT2 A and 5 -HT2 C subtypes. Modifying these early molecular steps within the serotonergic system alters the activity of signaling pathways in the central nervous system (CNS) and periphery, resulting in changes to baseline physiological function.


Muscarinic Acetylcholine Receptor Blockade

The drug also exhibits anticholinergic activity by engaging and blocking muscarinic acetylcholine receptors ( M1 - M3). This mechanism modulates key pathways associated with parasympathetic nervous system activity, leading to altered signaling intensity from endogenous mediators in systems controlling smooth muscle contraction and glandular secretions.

Dosage and Administration Information

How to Use Anarexol: Administration Guidelines

The administration of Cyproheptadine, the active component in Anarexol, is restricted to the oral route only, utilizing either the 4 mg scored tablet or the 2 mg/5 mL oral solution forms. The fundamental principle of its use is individualized dose titration to meet specific needs without exceeding maximum limits.

Administration and Dosing Schedule

Scope Instruction
Adult Dosing Treatment initiates at 4 mg taken three times a day (TID). The total daily dose should be adjusted upward until relief is attained, not exceeding 32 mg per day.
Dosing Frequency The dose must be administered in divided portions (two or three times daily) to provide a continuous therapeutic effect.
Timing The medicine may be taken without regard to meals.
Missed Dose Rule If a scheduled dose is missed, it should be taken as soon as possible, or skipped entirely if the time is near the next scheduled dose; double doses are not permitted.

Population-Specific Administration

Dosing requires specific adjustment for age and body size, adhering to strict limits.

  • Pediatric Patients: Dosing for children aged 2–6 years must not exceed a maximum of 12 mg per day. Children aged 7–14 years must not exceed 16 mg per day. Dose calculations may be based on body surface area (8 mg/m^2/ day).
  • Older Adults (Geriatric): Therapy must be initiated at the low end of the usual therapeutic range, and administration frequency may be reduced.

This procedural structure ensures that the use of the drug is systematically managed through low-dose initiation and careful dose titration within established boundaries.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anarexol

Evidence for Use in Chronic Urticaria (Hives) and Associated Pruritus

Research was studied for conditions characterized by fluctuating or episodic manifestations such as chronic urticaria (hives) and persistent allergic pruritus (itching). The study landscape includes Randomized Controlled Trials (RCTs), cross-over designs, and systematic reviews. These studies were used in research exploring how symptoms change over time. Outcomes monitored included Urticaria Activity Scores (UAS7), quality of life questionnaires, and patient-reported outcomes describing perceived discomfort.

Studies reported patterns observed during the measurement intervals over short and intermediate time frames. Research highlights changes measured in symptom severity and frequency, particularly in adults whose symptoms were observed in settings where initial treatments had proven insufficient. However, the evidence is limited by the fact that many of the core trials are older, and sample sizes were modest in some comparisons.


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Anarexol was studied for the relief of symptoms related to perennial and seasonal allergic rhinitis. Studies explored the agent in conditions involving periods of heightened symptoms by conducting comparative trials against placebo and other anti-allergy medications. Research examined outcomes related to physical discomfort using standardized metrics such as Total Symptom Scores (TSS).

The follow-up durations were typically short-term, which indicates that there is limited information for long-term outcomes or sustained effects. Comparative evidence explores measured results in the context of newer agents, and findings were mixed. Evidence quality varies across studies when analyzing older and newer trial methodologies.


What is Still Uncertain About Anarexol Research

The research landscape indicates several areas where further study was observed in some studies to be needed. Comparative evidence is lacking for many direct, contemporary comparisons. Additionally, subgroup findings are uncertain, as the majority of trials were not designed to specifically analyze or compare outcomes across different age, severity, or additional health conditions. The available evidence contributes to the broader evidence landscape, and research is ongoing.

Key Studies & References

  1. Cyproheptadine Drug Information (Official Monograph on Uses and Classification)

Frequently Asked Questions (FAQ)

Common questions about Anarexol (FAQ)


Q: Is Anarexol a narcotic or a controlled substance?

Official regulatory documents classify Anarexol (Cyproheptadine) as not being a controlled substance. The active ingredient has no scheduled listing under the Drug Enforcement Administration (DEA).


Q: How is Anarexol different from other drugs used for similar conditions?

Anarexol's active ingredient is officially described as having a dual action. It functions as a first-generation antihistamine, and it is also noted to act as an antiserotonergic agent. This dual function is a property noted in the official description of its pharmacology.


Q: Can Anarexol be used long-term?

Official product labeling indicates that long-term carcinogenic studies have not been conducted with the active ingredient, Cyproheptadine. The statement reports the absence of long-term studies.


Q: Is there a link between Anarexol and stomach discomfort?

Official product information lists several reported gastrointestinal adverse reactions. These reactions include epigastric distress (discomfort in the upper abdomen), nausea, and constipation.


Q: Can Anarexol be used by people with kidney issues?

Regulatory information indicates that the drug's elimination may be diminished in renal insufficiency (reduced kidney function). Official documentation notes that caution is required in patients with renal impairment, reflecting the diminished elimination.


Q: Is Anarexol suitable for elderly people?

The official product labeling states that Anarexol is contraindicated in elderly, debilitated patients. For other elderly individuals, official documents describe that cautious dose selection is necessary, typically initiating treatment at the low end of the therapeutic range.


Q: Does Anarexol cause weight gain or loss?

Official product documentation lists increased appetite and resulting weight gain as a reported adverse reaction associated with Anarexol.


Q: Can Anarexol be crushed or split?

The 4 mg tablet is officially supplied as a scored tablet, meaning it has a division line. For patients who cannot swallow tablets, liquid preparations like the oral solution or syrup are available.


Q: How long does Anarexol stay in your system?

Pharmacokinetic data suggests the elimination half-life of Anarexol's active ingredient is approximately 8.6 hours. Following a single administration, the elimination process occurs over several days, principally through urine and feces.


Q: Can Anarexol be used in teenagers?

Official documentation specifies dosing for children up to 14 years of age. For adolescents aged 15 years and older, official documentation indicates that the administration follows the adult approach.


Q: What happens if I miss a dose of Anarexol?

The official missed dose rule advises that if a scheduled dose is missed, it should be taken as soon as possible. However, if the time is near the next scheduled dose, the missed dose should be skipped entirely, as double doses are not permitted.


Q: Can Anarexol affect my mood?

Official adverse reaction lists include effects on the Central Nervous System. Reported reactions include changes like confusion, restlessness, excitation, nervousness, euphoria, and hallucinations.


Q: Are there known allergic reactions associated with Anarexol?

Yes, official adverse reaction lists include allergic manifestations such as rash and edema, and urticaria (hives). A known hypersensitivity (allergy) to the active ingredient is a formal contraindication for use.


Q: Can Anarexol be taken on an empty stomach?

Official administration instructions state that the medicine may be taken without regard to meals. This means it can be taken with food or on an empty stomach.


Q: What is the purpose of the inactive ingredients in the Anarexol tablet?

The inactive ingredients, or excipients, are substances combined with the active ingredient to form the final dosage unit. These ingredients help create the tablet structure, ensuring it is correctly formed, stable, and delivers the medicine properly.


Q: What happens in the body when Anarexol starts to work?

The active ingredient in Anarexol works by acting as an antagonist, meaning it binds to and blocks specific receptors for histamine and serotonin. This process results in the drug’s primary anticholinergic and sedative effects, which help alter the body’s physical response to these chemical messengers.


Q: Does Anarexol have a known antidote in case of accidental overuse?

Official regulatory documents address the management of overdosage, noting that supportive measures may be necessary, and specific agents like physostigmine salicylate may be considered in certain situations.


Q: Can Anarexol cause temporary changes to vision?

Yes, official reports of adverse reactions include blurred vision and diplopia (double vision). Overdosage may also cause vision changes, such as fixed or dilated pupils, due to its anticholinergic properties.


Q: Why is Anarexol restricted for use in people with certain heart conditions?

Anarexol's active ingredient is noted to have an 'atropine-like action,' which refers to its anticholinergic properties. Because of this action, official documents advise that the medicine should be used with caution in individuals with pre-existing cardiovascular disease and hypertension (high blood pressure).

How should Anarexol be stored and disposed of?

Storage and Handling Requirements

Anarexol (Cyproheptadine) must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medicine must be protected from light and excess moisture. Liquid forms should not be frozen. The product should be kept in a tightly closed container and stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Expired or unused Anarexol should not be flushed down the toilet or poured down the sink. The preferred method for disposal is through a secure drug take-back program. If a take-back option is unavailable, the drug can be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container for disposal in the household trash, following FDA guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Anarexol found in:

A-Z Index: